Home > Healthcare > Pharmaceuticals > Finished Drug Form > Cyclooxygenase 1 Inhibitor Market

Cyclooxygenase 1 Inhibitor Market Share

Report ID: GMI9901
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Cyclooxygenase 1 Inhibitor Market Share

The cyclooxygenase 1 inhibitor industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.

Cyclooxygenase 1 Inhibitor Market Companies

Some of the eminent market participants operating in the cyclooxygenase 1 inhibitor industry include:

Abbvie, Inc.
Alembic Limited
Aurobindo Pharma Limited
Boehringer Ingelheim International GmbH
Bayer AG
Cipla Limited
Hikma Pharmaceuticals PLC
Johnson & Johnson
Novartis AG
Pfizer Inc.
Sabinsa
Teva Pharmaceutical Industries Ltd
Torrent Pharmaceuticals Limited
Viatris Inc.
Zydus Lifesciences Limited

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Global cyclooxygenase 1 inhibitor industry was valued at USD 69.6 billion in 2023 and is anticipated to register 7.6% CAGR between 2024 and 2032 due to the increasing prevalence of inflammatory diseases and technological advancements in drug development.

The hospital pharmacy segment in the market is estimated to account for USD 60.9 billion by 2032 due to extensive medication ranges, expert pharmacist management, and collaboration with healthcare teams.

The selective cox 1 inhibitor segment in the cyclooxygenase 1 inhibitor market is expected to reach USD 96.5 billion by 2032 due to reduced GI side effects and effective antiplatelet action for improving safety and efficacy compared to non-selective NSAIDs.

Abbvie, Inc., Alembic Limited, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Bayer AG, Cipla Limited, Hikma Pharmaceuticals PLC, Johnson & Johnson, Novartis AG, and Pfizer Inc., among others.